Core Viewpoint - Huakang Clean announced a financial adjustment to reflect a more accurate representation of its financial status and operational results, involving impairment testing and provisions for asset impairment [1] Financial Adjustments - The company and its subsidiaries conducted impairment tests on various assets showing signs of impairment, in accordance with the relevant provisions of the Accounting Standards for Enterprises and company accounting policies [1] - A total of 27.28 million yuan was recognized as credit impairment losses and asset impairment losses for the third quarter of 2025 [1]

Core Insights - The company reported a revenue of 596,573,255.91 yuan for the third quarter of 2025, representing a year-on-year growth of 13.48% [1] - The net profit attributable to shareholders of the listed company was 42,473,687.54 yuan, showing a year-on-year increase of 39.69% [1] Financial Performance - Revenue for Q3 2025: 596.57 million yuan, up 13.48% year-on-year [1] - Net profit for Q3 2025: 42.47 million yuan, up 39.69% year-on-year [1]

Core Points - Huakang Clean (301235) announced its intention to win the bid for the medical special construction and installation subcontracting project of Wuyi New District Comprehensive Hospital (Phase I) with a bid amount of approximately 100 million yuan [1] - The contract duration is set for 246 calendar days [1] - The project includes medical special construction and installation, which must comply with current engineering construction quality acceptance standards and relevant national, industry, and local acceptance standards [1] Project Details - The project requires compliance with various acceptance standards, including civil defense and fire safety [1] - The procurement quality standards mandate the purchase of original and authentic brand equipment or materials [1] - All purchased equipment or materials must meet the requirements set by the selection personnel and the quality specifications established by relevant departments [1]

转债代码：123251 转债简称：华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025-126 武汉华康世纪洁净科技股份有限公司 关于项目预中标的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示：本项目仍处于中标候选人公示阶段，获取中标通知书、签约等后 续工作尚具有一定不确定性，敬请广大投资者注意投资风险。武汉华康世纪洁净 科技股份有限公司（以下简称"公司"）将根据相关事项后续进展情况履行相应 的信息披露义务。 公司于近日参与了"武夷新区综合医院（一期）工程医用专项施工及安装分 包"项目的投标，招标单位为南平建设集团有限公司。2025 年 10 月 24 日，中国 招标投标公共服务平台（http://www.cebpubservice.com）发布了相关中标候选 人公示。现将具体预中标情况提示如下： 一、预中标项目概况 1、招标单位名称：南平建设集团有限公司 3、项目名称：武夷新区综合医院（一期）工程医用专项施工及安装分包 4、第一名中标候选人：武汉华康世纪洁净科技股份有限公司 5、中标价：100,257,633.33 ...

| 证券代码:301235 | | --- | | 转债代码:123251 | 证券代码：301235 证券简称：华康洁净 公告编号：2025-124 转债代码：123251 转债简称：华医转债 武汉华康世纪洁净科技股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第三次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公 司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025年11月10日14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2025年 11月10日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系 统投票的具体时间为2025年11月10日9:15至15:00的任意 ...

| 证券代码：301235 | 证券简称：华康洁净 | 公告编号：2025-119 | | --- | --- | --- | | 转债代码：123251 | 转债简称：华医转债 | | 武汉华康世纪洁净科技股份有限公司 第二届监事会第二十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）第二届监事会第二 十五次会议于 2025 年 10 月 23 日（星期四）在公司会议室以现场方式召开。会议通 知已于 2025 年 10 月 20 日以邮件、通讯方式通知到各位监事。本次会议由监事会主 席彭胡杨先生主持，应到监事 3 人，实到监事 3 人。董事会秘书彭沾先生列席了会 议。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《武汉华康世纪洁净科技 股份有限公司章程》（以下简称"《公司章程》"）以及有关法律、法规的规定。 二、监事会会议审议情况 会议以记名投票表决的方式，一致通过了以下议案： （一）审议通 ...

转债代码：123251 转债简称：华医转债 证券代码：301235 证券简称：华康洁净 公告编号：2025-118 武汉华康世纪洁净科技股份有限公司 第二届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 经出席会议的全体董事认真审议，通过了以下议案： 1、审议通过《关于<2025 年第三季度报告>的议案》 公司董事会编制的《2025 年第三季度报告》的程序符合法律、行政法规和 中国证券监督管理委员会的相关规定，报告内容真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏。 武汉华康世纪洁净科技股份有限公司（以下简称"公司"）第二届董事会第 二十七次会议于 2025 年 10 月 23 日（星期四）在公司会议室以通讯方式召开。 会议通知于 2025 年 10 月 20 日以电话及邮件方式送达全体董事。本次会议应到 董事 7 人，实到董事 7 人。会议由董事长谭平涛先生主持，公司监事及高级管理 人员列席了会议。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（ ...

Financial Performance - The company's revenue for Q3 2025 reached ¥596,573,255.91, representing a year-over-year increase of 13.48% and a cumulative increase of 32.59% for the year-to-date period[5] - Net profit attributable to shareholders for Q3 2025 was ¥42,473,687.54, a significant increase of 39.69% year-over-year, with a year-to-date net profit of ¥61,156,713.68, reflecting a remarkable growth of 211.46%[5] - The basic earnings per share for Q3 2025 was ¥0.40, up 37.93% compared to the same period last year, while the diluted earnings per share also stood at ¥0.40[5] - Total operating revenue for the current period reached ¥1,431,484,708.54, an increase of 32.5% compared to ¥1,079,614,618.16 in the previous period[24] - Operating profit for the current period was ¥75,103,733.85, significantly higher than ¥21,609,135.36 in the previous period, reflecting a growth of 248.5%[24] - The total profit for the current period is 72,001,011.63, compared to 21,575,783.19 in the previous period, indicating a significant increase[25] - The net profit attributable to shareholders of the parent company is 61,156,713.68, up from 19,635,357.61, reflecting a growth of approximately 211%[25] - Basic and diluted earnings per share for the current period are both 0.77, compared to 0.19 in the previous period, marking a substantial increase[25] - The total comprehensive income for the current period is 62,939,203.70, compared to 19,522,498.54 in the previous period[25] Assets and Liabilities - Total assets as of September 30, 2025, were ¥4,043,426,756.92, a decrease of 4.33% from the end of the previous year[5] - The company reported a significant increase in accounts receivable, which rose by 223.50% to ¥18,317,142.70, primarily due to an increase in bank acceptance bills[10] - The company's total liabilities decreased to ¥2,184,445,662.39 from ¥2,422,870,314.33, a reduction of 9.8%[22] - The company’s investment income surged by 1595.84% to ¥497,464.67, primarily driven by increased returns from financial investments[12] - The company experienced a 31.20% increase in contract liabilities, reaching ¥564,091,518.63, attributed to an increase in orders and advance payments[11] - The company reported a net credit impairment loss of ¥-44,699,276.28, an improvement from ¥-54,755,308.55 in the previous period[24] Cash Flow - The company's cash flow from operating activities showed a negative net amount of ¥-304,696,222.79, indicating a decline of 163.33% year-to-date[5] - The net cash flow from operating activities for the first nine months of 2025 was -$304.70 million, a decrease of 163.33% compared to -$115.71 million in the same period of 2024, primarily due to increased procurement payments and tax expenses[13] - The net cash flow from investing activities decreased by 83.14%, amounting to -$20.68 million, attributed to an increase in the maturity of financial products during the reporting period[13] - The net cash flow from financing activities was -$196.99 million, a decline of 207.58% from $183.12 million in the previous year, mainly due to reduced new borrowings and increased loan repayments[13] - The net increase in cash and cash equivalents was -$522.37 million, representing a significant decrease of 845.72% compared to -$55.24 million in the same period last year, influenced by the reductions in operating and financing cash flows[13] - Operating cash flow for the current period is -304,696,222.79, worsening from -115,709,862.52 in the previous period[26] - Cash received from sales of goods and services increased to 1,475,937,326.50 from 1,041,658,045.87, representing a growth of about 42%[26] - The cash and cash equivalents at the end of the period stand at 422,935,583.56, down from 117,312,982.00 in the previous period[27] Shareholder Information - As of September 30, 2025, the total number of ordinary shareholders was 10,713, with no preferred shareholders having restored voting rights[15] - The largest shareholder, Tan Pingtao, holds 43.34% of the shares, totaling 46,708,990 shares, with 35,031,742 shares under lock-up[15] - The top ten shareholders collectively hold significant stakes, with the second-largest being Sunshine Life Insurance Co., Ltd. at 5.00%[15] - The total number of restricted shares held by Tan Pingtao was 46,708,990, all of which were released from lock-up on July 28, 2025[18] - The company has a repurchase account holding 3,403,400 shares, accounting for 3.16% of the total share capital, which is not included in the top ten shareholders[16] - There are no significant changes in the shareholder structure due to margin trading activities among the top ten shareholders[16] Operational Metrics - Total operating costs amounted to ¥1,311,730,583.88, up 29.8% from ¥1,010,799,535.25 in the prior period[24] - Current assets totaled ¥3,198,184,063.27, a decrease of 5.9% from ¥3,397,800,728.82 at the beginning of the period[22] - Cash and cash equivalents decreased to ¥478,283,028.05 from ¥1,047,947,259.79, representing a decline of 54.3%[22] - Accounts receivable increased to ¥1,806,725,473.48, up 10.4% from ¥1,636,513,574.86[22] - Inventory rose to ¥644,461,786.19, an increase of 27.0% compared to ¥508,182,005.02 at the beginning of the period[22] Audit Status - The company has not undergone an audit for the third quarter financial report[28]

国联民生证券承销保荐有限公司 关于武汉华康世纪洁净科技股份有限公司 使用部分闲置募集资金暂时补充流动资金 的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生"或"保荐机构"）作 为武汉华康世纪洁净科技股份有限公司（以下简称"华康洁净"或"公司"）2022 年首次公开发行股票并在创业板上市、2024年向不特定对象发行可转换公司债券之 保荐机构，根据《证券发行上市保荐业务管理办法》、《上市公司募集资金监管规 则》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等相关规定，对公司使用部分闲置募 集资金暂时补充流动资金事项进行了核查，核查的具体情况如下： 一、募集资金基本情况 （一）首次公开发行股票募集资金 经中国证券监督管理委员会《关于同意武汉华康世纪医疗股份有限公司首次公 开发行股票注册的批复》（证监许可[2021]4121号）同意注册，并经深圳证券交易所 同意，公司向社会公开发行了人民币普通股（A股）股票2,640.00万股，发行价为每 股人民币39.30元，共计募集资金总额为人民币103,752.00万元，扣除发行费用8,801.72 ...

武汉华康世纪洁净科技股份有限公司 董事、高级管理人员持有和买卖本公司 股票管理制度 二〇二五年十月 武汉华康世纪洁净科技股份有限公司董事、高级管理人员持有和买卖本公司股票管理制度 目录 | 第一章 总则 | | 1 | | --- | --- | --- | | 第二章 | 买卖本公司股票行为的申报 | 2 | | 第三章 | 所持本公司股份可转让的一般原则和规定 | 3 | | 第四章 | 买卖公司股票的禁止情况 | 3 | | 第五章 | 持有及买卖公司股票行为的披露 | 5 | | 第六章 处罚 | | 7 | | 第七章 附则 | | 7 | 武汉华康世纪洁净科技股份有限公司董事、高级管理人员持有和买卖本公司股票管理制度 第一章 总则 第一条 为加强武汉华康世纪洁净科技股份有限公司（以下简称"公司"或 "本公司"）对董事、高级管理人员持有及买卖本公司股份的管理工作，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上市公司董事和高级管理人员所持 本公司股份及其变动管理规则》《深圳证券交易所上市公司自律监管指引第2号 ——创业板上市公司规范 ...